LORATADINE- loratadine tablet, orally disintegrating 
Advagen Pharma Limited

----------

Drug Facts
Active ingredient (in each tablet)                                                                  Purpose
Loratadine USP, 10 mg………………………………….....................Antihistamine
Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: ■ runny nose ■ itchy, watery eyes ■ sneezing ■ itching of the nose or throat
Warnings
Do not use if you have ever had an allergic reaction to this product or any of its ingredients.
Ask a doctor before use if you have liver or kidney disease. Your doctor should determine if you need a different dose.
When using a product do not take more than directed. Taking more than directed may cause drowsiness.
Stop use and ask a doctor if an allergic reaction to this product occurs.
Seek medical help right away.
If pregnant or breast-feeding, ask a health professional before use.
Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.
Directions
  • place 1 tablet on tongue; tablet disintegrates, with or without water
adults and children 6 years and over 1 tablet daily; not more than 1 tablet in 24 hours
Children under 6 years of age ask a doctor
Consumers with liver or kidney disease ask a doctor
Other information
  • Phenylketonurics: contains phenylalanine (a component of aspartame) 1.52 mg per 10 mg orally disintegrating tablet.
  • safety sealed: do not use if the individual blister unit imprinted with Loratadine Orally Disintegrating Tablets USP 10 mg is open or torn
  • store between 20° to 25°C (68° to 77°F)
  • use tablet immediately after opening individual blister
  • FDA approved acceptance criteria for assay and organic impurities differs from USP test
Inactive ingredients
aspartame, colloidal silicon dioxide, crospovidone, magnesium stearate, maize starch, mannitol, microcrystalline cellulose, peppermint flavor, sodium stearyl fumarate
Questions or comments?
Advagen - 888-413-0949
Distributed by:
Advagen Pharma Ltd
666 Plainsboro Road
Suite 605
Plainsboro, NJ 08536, USA.

Manufactured by:
Rubicon Research Private Limited
Ambernath, Dist: Thane, 421506 India.

Note: Imprint Code - Λ indicated as UpArrowhead in Drug Listing Data Element (DLDE) section.

PRINCIPAL DISPLAY PANEL

Loratadine Orally Disintegrating Tablets USP 10 mg - 10 Tablets - NDC 72888-029-09

loratadine-odt-usp-10mg-10count

Loratadine Orally Disintegrating Tablets USP 10 mg - 30 Tablets - NDC 72888-029-11

loratadine-odt-usp-10mg-30count

LORATADINE 
loratadine tablet, orally disintegrating
Product Information
Product TypeHUMAN OTC DRUGItem Code (Source)NDC:72888-029
Route of AdministrationORAL
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
LORATADINE (UNII: 7AJO3BO7QN) (LORATADINE - UNII:7AJO3BO7QN) LORATADINE10 mg
Inactive Ingredients
Ingredient NameStrength
ASPARTAME (UNII: Z0H242BBR1)  
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
CROSPOVIDONE (UNII: 2S7830E561)  
MAGNESIUM STEARATE (UNII: 70097M6I30)  
STARCH, CORN (UNII: O8232NY3SJ)  
MANNITOL (UNII: 3OWL53L36A)  
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)  
SODIUM STEARYL FUMARATE (UNII: 7CV7WJK4UI)  
Product Characteristics
Colorwhite (White to Off-White) Scoreno score
ShapeROUNDSize10mm
FlavorPEPPERMINTImprint Code UpArrowhead43
Contains    
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:72888-029-091 in 1 CARTON09/10/2020
110 in 1 BLISTER PACK; Type 0: Not a Combination Product
2NDC:72888-029-113 in 1 CARTON09/10/2020
210 in 1 BLISTER PACK; Type 0: Not a Combination Product
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
ANDAANDA21428009/10/2020
Labeler - Advagen Pharma Limited (051627256)
Registrant - Rubicon Research Private Limited (918629544)
Establishment
NameAddressID/FEIBusiness Operations
Rubicon Research Private Limited677604197manufacture(72888-029) , analysis(72888-029) , pack(72888-029)

Revised: 9/2020
Document Id: b021e919-4cb9-09f4-e053-2a95a90a4327
Set id: a5699a95-c0a7-43ea-9bab-bbfaba3c8aa5
Version: 1
Effective Time: 20200925
 
Advagen Pharma Limited